The risk of preterm birth was 37% higher for mothers involved in a phase 3 respiratory syncytial virus maternal vaccine trial than the control group in a clinical trial led by pharmaceutical giant GSK and researchers from Durham, N.C.-based Duke University School of Medicine.
Read the full post on Becker's Hospital Review | Healthcare News & Analysis
